Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity

The CD20-directed monoclonal antibody rituximab (RTX) established a new era in the treatment of non-Hodgkin lymphoma (NHL); however, suboptimal response and/or resistance to RTX still limit its clinical merits. Although four effector mechanisms are validated to participate in CD20-based immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hua-Fei, Wu, Cong, Chen, Ting, Zhang, Ge, Zhao, He, Ke, Chang-Hong, Xu, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525799/
https://www.ncbi.nlm.nih.gov/pubmed/26257518
http://dx.doi.org/10.2147/IJN.S80129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525799/
https://www.ncbi.nlm.nih.gov/pubmed/26257518
http://dx.doi.org/10.2147/IJN.S80129

Ejemplares similares